Dong Sung Bio Pharm.Co.,Ltd.
Korea ExchangeTotal Valuation
Dong Sung Bio Pharm.Co.,Ltd. carries a market capitalization of 23.75B, placing it among publicly traded companies globally. Its enterprise value stands at -99.48B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 23.75B |
| Enterprise Value | -99.48B |
Share Statistics
Dong Sung Bio Pharm.Co.,Ltd. currently has 96.62M shares outstanding.
| Shares Outstanding | 96.62M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 2.03 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2.05 |
Financial Position
Dong Sung Bio Pharm.Co.,Ltd. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.68, indicating elevated leverage, while an interest coverage ratio of -4.02 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.17 |
| Quick Ratio | 0.91 |
| Debt / Equity | 68.68 |
| Debt / EBITDA | -6.57 |
| Interest Coverage | -4.02 |
Financial Efficiency
| Return on Equity (ROE) | -54.42 |
| Return on Assets (ROA) | -10.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 256.80 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.12 |
Taxes
Over the trailing twelve months, Dong Sung Bio Pharm.Co.,Ltd. has paid -2.84B in income taxes, reflecting an effective tax rate of 123.92.
| Income Tax | -2.84B |
| Effective Tax Rate | 123.92 |
Stock Price Statistics
Dong Sung Bio Pharm.Co.,Ltd.'s stock has declined approximately -79.75026% over the past 52 weeks. The 50-day moving average sits at 3,910.60, while the 200-day moving average is 4,423.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | -79.75026% |
| 50-Day Moving Average | 3,910.60 |
| 200-Day Moving Average | 4,423.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Dong Sung Bio Pharm.Co.,Ltd. generated 79.95B in revenue and converted that into -24.42B in net income, yielding earnings per share of -998.92. EBITDA reached -9.77B, while operating income came in at -9.77B.
| Revenue | 79.95B |
| Gross Profit | 33.63B |
| Operating Income | -9.77B |
| Pretax Income | -27.26B |
| Net Income | -24.42B |
| EBITDA | -9.77B |
| EBIT | -9.77B |
| Earnings Per Share (EPS) | -998.92 |
Balance Sheet
Dong Sung Bio Pharm.Co.,Ltd. holds 163.61B in cash and equivalents against 64.13B in total debt, resulting in a net debt position of -99.53B. Total book value stands at 62.15B, with working capital of 29.80B providing operational flexibility.
| Cash & Cash Equivalents | 163.61B |
| Total Debt | 64.13B |
| Net Debt | -99.53B |
| Equity (Book Value) | 62.15B |
| Book Value Per Share | 2,542.59 |
| Working Capital | 29.80B |
Cash Flow
Dong Sung Bio Pharm.Co.,Ltd. produced -1.52B in operating cash flow over the past twelve months. After subtracting -157.28M in capital expenditures, free cash flow totaled -1.67B - equivalent to -68.48 per share.
| Operating Cash Flow | -1.52B |
| Capital Expenditures | -157.28M |
| Free Cash Flow | -1.67B |
| FCF Per Share | -68.48 |
Margins
Dong Sung Bio Pharm.Co.,Ltd. operates with a gross margin of 42.07, reflecting its pricing power and cost economics. The operating margin of -12.22 and net profit margin of -30.54 provide insight into operational efficiency.
| Gross Margin | 42.07 |
| Operating Margin | -12.22 |
| Pretax Margin | -34.09 |
| Profit Margin | -30.54 |
| EBITDA Margin | -12.22 |
Stock Splits
Dong Sung Bio Pharm.Co.,Ltd.'s most recent stock split took place on December 22, 2008 with a 1:5 split ratio.
| Last Split Date | 12/22/2008 |
| Split Ratio | 1:5 |
Scores
Dong Sung Bio Pharm.Co.,Ltd. posts an Altman Z-Score of 0.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.12 |